TY - JOUR
T1 - The place of GLP-1-based therapy in diabetes management
T2 - Differences between DPP-4 inhibitors and GLP-1 receptor agonists
AU - Eckerle Mize, Dara L.
AU - Salehi, Marzieh
N1 - Funding Information:
Acknowledgement Marzieh Salehi has received an NIH grant (DK083554).
PY - 2013/6
Y1 - 2013/6
N2 - Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.
AB - Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.
KW - Cardiovascular risk factors
KW - DPP-4
KW - DPP-4 inhibitors
KW - GLP-1
KW - GLP-1 receptor agonists
KW - Hypoglycemia
KW - Incretin
KW - Type 2 diabetes
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=84877757399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877757399&partnerID=8YFLogxK
U2 - 10.1007/s11892-013-0377-9
DO - 10.1007/s11892-013-0377-9
M3 - Article
C2 - 23479200
AN - SCOPUS:84877757399
SN - 1534-4827
VL - 13
SP - 307
EP - 318
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 3
ER -